CEO Lisa Conte mentions the interest in partnering with institutional investors and expanding global exposure. The company has rights to Proflo and existing partnerships. Dr. Pravin Credi discusses the extension data from the 12-week on-target trial, focusing on responder analysis and signals from the second stage.